Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ficlatuzumab × Thoracic × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 491 Cisplatin 362 Pemetrexed 359 Paclitaxel 244 Docetaxel 230 Gemcitabine 193 Bevacizumab 177 pembrolizumab 170 Radiotherapy 164 Erlotinib Hydrochloride 160 Etoposide 133 durvalumab 129 Nivolumab 120 Drug Therapy 110 osimertinib 91 atezolizumab 82 Gefitinib 69 Vinorelbine 63 Radiosurgery 62 anlotinib 52 130-nm albumin-bound paclitaxel 46 tislelizumab 45 Ipilimumab 45 Irinotecan 44 Surgical Procedures, Operative 43 Albumin-Bound Paclitaxel 42 Topotecan 41 Taxes 41 apatinib 40 Magnetic Resonance Spectroscopy 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02318368 2020-10-22

FOCAL

AVEO Pharmaceuticals, Inc.

Phase 2 Terminated

10 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡